Cell Line Development Market Is Predicted To Grow Swiftly Due To Increasing Demand For Effective Cancer Therapeutics Till 2022: Grand View Research, Inc.
Global cell line development market size is expected to
reach USD 6.24 billion by 2022, according to a new report by Grand View
Research, Inc. The Increasing demand for monoclonal antibodies and patent
expiration of blockbuster biologics are expected to drive the cell line
development industry over the forecast period.
Increasing prevalence of
autoimmune diseases and cancer are likely to increase the demand for accurate
and cost effective treatment options which is expected to render a positive
impact on market growth. In addition, improving healthcare infrastructure,
economic development and favorable government initiatives promoting the growth
of the biotechnology industry are factors contributing towards the growth of
the cell line development market.
Ongoing R&D for stable &
authentic cell lines and the introduction of technologically advanced processes
such as single use bioreactor and micro bioreactor for large scale
bioproduction are further expected to provide this market with lucrative future
growth opportunities.
U.S. cell line development market, by type, 2012 - 2022
(USD Million)
Browse full research report on
Cell
Line Development Market Analysis:
Further key findings from the report suggest:
- Reagent and
media was the largest product market in 2014, owing to increasing number
of cell culture procedures. Reagent and media are necessary components
involved in cell line development procedures & cell culture and are
cost intensive in nature. The market for reagent and media was valued at
over 1.0 billion in 2014.
- Mammalian
cell lines were widely used as a source for cell line development in 2014,
owing to associated advantages such as accurate complex protein expression
nature, critical for the production of monoclonal antibodies, vaccines,
and biologics.
- Cell line
development finds the largest application in the bioproduction of
biologics, vaccines, Mabs, therapeutic proteins and biosimilars. Rising
demand for monoclonal antibodies and vaccines are expected to boost the
growth of this segment over the forecast period. The market for cell line
development based bioproduction is also expected to witness lucrative
growth of over 12.5% during the forecast period.
- North America
was the largest market in 2014, with revenue estimated at over 800
million. The region’s market dominance is attributed to factors such as
the growing adoption rates of cell culture techniques, presence of well
developed healthcare infrastructure, supportive government initiatives and
high healthcare expenditure levels.
- Asia Pacific
cell line development market is anticipated to register rapid growth over
the forecast period owing to factors such as the presence of high unmet
needs, rising number of CROs (Contract Research Organization) providing
pertinent services, growing R&D investments aimed at the development
of stable cell lines and increasing biologics production.
- Key players
in this market include European Collection of cell Cultures (ECACC), Lonza
Group AG, GE Healthcare, Thermo Fisher Scientific Inc., Sartorious AG,
Selexis SA, Wuxi AppTec Inc., Sigma-Aldrich Corporation, American Type
Culture Collection (ATCC) and Corning Inc.
Comments
Post a Comment